Addex Therapeutics Ltd (NASDAQ:ADXN) Sees Large Decrease in Short Interest

Addex Therapeutics Ltd (NASDAQ:ADXN) was the target of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 15,300 shares, a decline of 16.8% from the November 15th total of 18,400 shares. Based on an average daily volume of 44,300 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.9% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $30.00 price target on shares of Addex Therapeutics in a research report on Wednesday, October 2nd.

Addex Therapeutics Price Performance

Shares of Addex Therapeutics stock opened at $8.00 on Friday. Addex Therapeutics has a 1-year low of $5.00 and a 1-year high of $27.90. The company has a market capitalization of $8.48 million, a P/E ratio of -23.53 and a beta of 1.74. The business’s fifty day moving average price is $9.40 and its two-hundred day moving average price is $9.01.

Addex Therapeutics (NASDAQ:ADXN) last released its earnings results on Monday, September 30th. The company reported ($1.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($1.70). The firm had revenue of $0.13 million during the quarter, compared to analyst estimates of $0.26 million. Addex Therapeutics had a negative return on equity of 112.43% and a net margin of 850.30%. On average, research analysts expect that Addex Therapeutics will post 9.8 earnings per share for the current fiscal year.

Addex Therapeutics Company Profile

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.